ArticleAnnals of nuclear medicine2026
A real-world decision tree model based on ¹⁸F-FDG PET/CT Z scores and Mini-Mental State Examination for differentiating mild cognitive impairment from clinically diagnosed Alzheimer disease.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the ability of regional metabolic Z scores derived from ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT), medial temporal atrophy (MTA) scores, and Mini-Mental State Examination (MMSE) results to distinguish mild cognitive impairment (MCI) from clinically diagnosed Alzheimer disease (AD), and to develop an interpretable decision-tree model based on these parameters.
methodsThis retrospective single-center study included 124 patients who underwent ¹⁸F-FDG PET/CT for suspected cognitive impairment between 2023 and 2025. Patients were classified as AD or MCI according to final clinical diagnoses established by experienced neurologists using National Institute on Aging-Alzheimer's Association criteria. Regional metabolic Z scores were generated with CortexID Suite by comparison with an age-matched healthy normative database. MTA was graded on structural magnetic resonance imaging using the Scheltens scale by two blinded nuclear medicine physicians. MMSE scores were retrieved from clinical records. A random forest algorithm was used to identify discriminative variables, which were then incorporated into a transparent decision-tree classifier. The dataset was divided into a training cohort (n = 100) and a split-sample test cohort (n = 24).
resultsThe final decision tree integrated regional metabolic Z scores and MMSE values in a hierarchical classification structure. In the split-sample test cohort, the model achieved an accuracy of 95.8% and a balanced accuracy of 96.4%, with 100% sensitivity and 92.9% specificity for AD classification. The area under the receiver operating characteristic curve was 0.964 (95% confidence interval, 0.894-1.000).
conclusionsAn interpretable decision-tree approach integrating quantitative ¹⁸F-FDG PET/CT metrics with cognitive assessment showed promising performance for distinguishing clinically diagnosed AD from MCI in a real-world clinical cohort.
Indexed as
Identifiers
42423959What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.